logo
logo
Sign in

Anti-malarial Drugs Market, Size, Share 2021-2028

avatar
vikram pathari
Anti-malarial Drugs Market, Size, Share 2021-2028

Market Overview

Malaria is an infectious disease, which spreads through a bite of an infected female Anopheles mosquito, transferring parasites into the human body. Merozoites grow inside the red cells and destroy them, which further cause symptoms such as fever, tiredness, vomiting, and headache. The drugs that are used to treat and prevent malarial infections are called antimalarial.

The global anti-malarial drugs market size was valued US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).


Download Free Sample: https://www.datamintelligence.com/download-sample/anti-malarial-drugs-market


Market Dynamics

The market is predicted to grow due to increased research for novel medications and new combination therapies.

The different levels of the innovation system of antimalarial therapies in Nigeria and Burkina Faso are identified. The innovation systems approach explores the readiness of African countries for a transition to TACTs. The innovation systems approach assumes that integrating new technology in society is a collective effort in a complex social system. Triple artemisinin-based combination therapies (TACTs) are being developed to respond to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs can benefit the larger community and future patients by mitigating the risk of drug resistance. This approach has become a well-established analytical tool in transition studies to generate insight into innovation barriers and define policy implications accordingly.

Side effects associated with anti-malaria drugs are expected to hamper market growth.

Most anti-malarial drugs are associated with severe side effects, which is expected to decrease demand for these drugs. For instance, Hydroxychloroquine main side effects are gastrointestinal upset (vomiting, diarrhea, stomach cramps), skin rash, headache, dizziness, and ocular toxicity. However, serious side effects, including arrhythmia, bronchospasm, angioedema, and seizures, rarely occur. Such factors are expected to hamper market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has resulted in millions of infections, hundreds of thousands of deaths and major societal disruption due to lockdowns and other restrictions introduced to limit disease spread. Relatively little attention has been paid to understanding how the pandemic has affected malaria treatment, prevention, and control, which is a major cause of death and disease and predominantly affects people in less well-resourced settings. Malaria programs are being affected in many ways by COVID-19. To prevent malaria, insecticide-treated nets need regular

renewal, but distribution campaigns have been delayed or canceled. For detection and treatment of malaria, individuals may stop attending health facilities out of fear of exposure to COVID-19 or because they cannot afford transport. Health care workers require additional resources to protect themselves from COVID-19. Supplies of diagnostics and drugs are being interrupted, compounded by the production of substandard and falsified medicines and diagnostics. These disruptions are predicted to double the number of young African children dying of malaria in the coming year and may impact efforts to control the spread of drug resistance. However, the situation is expected to improve gradually in the forecast period.


Segment Analysis

By Malaria Type

Plasmodium falciparum

Plasmodium malariae

Plasmodium vivax 

Plasmodium ovale

Plasmodium knowlesi

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies


Geographical Analysis

Middle East & Africa region holds the largest market share in the global anti-malarial drugs market

In 2020, the Middle East and Africa accounted for the highest revenue share. The region growth is attributed to the owing rapid surge in prevalence of malaria in the region. According to the World Health Organization, malaria is caused by five parasitic species, two of which – P. falciparum and P. vivax – are the most dangerous. The malaria parasite Plasmodium falciparum is the deadliest and most common on the African continent. In most places outside of Sub-Saharan Africa, P. vivax is the most common malaria parasite.

Moreover, the African region carries a disproportionately high share of the global malaria burden. In 2019, the region was home to 94% of all malaria cases and deaths. Nigeria (23 percent), the Democratic Republic of the Congo (11 percent), the United Republic of Tanzania (5 percent), Burkina Faso (4 percent), Mozambique (4 percent), and Niger (4 percent) accounted for over half of all malaria deaths globally (4 percent). Therefore, the above statements it has increased the demand for anti-malarial drugs. Thus, the Middle East and Africa region has led to the highest market share in the forecast period.


Competitive Landscape

Major key players in the anti-malarial drugs market are GlaxoSmithKline PLC, Cipla, Mylan N.V., F. Hoffmann-La Roche AG, Novartis AG, Ipca Laboratories Ltd. and Alvizia Health Care. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of the anti-malarial drugs market globally. For instance, On February 4, 2021, Zydus Cadila announced that its antimalarial compound ZY19489 (MMV253) is in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has completed Phase I clinical evaluation [Reg’n Number ACTRN12619000127101]. In the first human study conducted in Australia, escalating doses of 25 to 1500 mg were administered to healthy human volunteers. A safety data review committee evaluated emerging pharmacokinetic (PK) and safety data.

Ipca Laboratories Limited:

Overview:

Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai, India. The company has been a crucial healthcare partner in over 120 countries across the 6 continents. It is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Moreover, the company is one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva. It has leading brands in Pain, Rheumatology, Antimalarials and Haircare therapy. Additionally, four formulations rank amongst the top 300 brands of IPM as per IQVIA.


View full report: https://www.datamintelligence.com/research-report/anti-malarial-drugs-market

Enquiry before buying: https://www.datamintelligence.com/enquiry/anti-malarial-drugs-market

 

About Us 

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

 

For more information: 

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

 

collect
0
avatar
vikram pathari
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more